Levi & Korsinsky Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 – NTLA
Portfolio Pulse from
Levi & Korsinsky law firm is pursuing a class action securities lawsuit against Intellia Therapeutics, alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting the NTLA-3001 research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
March 26, 2025 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ongoing class action lawsuit and program discontinuation may negatively impact investor confidence and stock performance
The lawsuit alleges material misrepresentations about the NTLA-3001 program, which could result in financial penalties and reduced investor trust. Stock price already experienced a significant drop following the announcement.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100